NASDAQ:TRML • US89157D1054
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TOURMALINE BIO INC (TRML).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-15 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2025-09-11 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2025-09-10 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-09-10 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-09-10 | Truist Securities | Downgrade | Buy -> Hold |
| 2025-09-10 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-09-09 | LifeSci Capital | Downgrade | Outperform -> Market Perform |
| 2025-09-09 | Wedbush | Downgrade | Outperform -> Neutral |
| 2025-09-09 | Jefferies | Downgrade | Buy -> Hold |
| 2025-08-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-14 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-05-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-23 | Chardan Capital | Initiate | Buy |
| 2025-03-14 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-03-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-06 | Wedbush | Initiate | Outperform |
| 2025-02-24 | LifeSci Capital | Initiate | Outperform |
| 2024-12-11 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-12-11 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-06 | BMO Capital | Initiate | Outperform |
| 2024-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A -54.74% | N/A 660.86% | N/A 186.12% | N/A 219.53% | N/A 111.18% | |||||||
| EBITDA YoY % growth | -18M | -22.23M -23.50% | -46.89M -110.93% | -74.9M -59.74% | -45.376M 39.42% | -89.693M -97.67% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -18.38M | -22.68M -23.39% | -47.51M -109.48% | -76.28M -60.56% | -45.409M 40.47% | -89.732M -97.61% | N/A -16.02% | N/A -27.73% | N/A -47.92% | N/A -18.50% | N/A 8.14% | N/A 26.33% | N/A 93.61% | N/A 2,982.47% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -5.53 | -17.90 -223.69% | N/A 80.42% | -2.87 18.11% | N/A -33.34% | N/A -9.09% | N/A -11.21% | N/A -3.26% | N/A 13.62% | N/A 17.73% | N/A 264.07% | N/A 254.56% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.98 -25.36% | -1.02 -18.25% | -1.04 -16.44% | -1.04 -15.24% | -1.00 -2.77% | -1.01 1.12% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -27.653M -15.22% | -28.778M -11.52% | -31.045M -18.35% | -33.308M -28.24% | -36.227M -31.01% | -39.496M -37.24% |
All data in USD
15 analysts have analysed TRML and the average price target is 48.96 USD. This implies a price increase of 2.04% is expected in the next year compared to the current price of 47.98.
TOURMALINE BIO INC (TRML) will report earnings on 2026-03-11, after the market close.
The consensus EPS estimate for the next earnings of TOURMALINE BIO INC (TRML) is -0.98 USD and the consensus revenue estimate is 0 USD.
The consensus rating for TOURMALINE BIO INC (TRML) is 70.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.